Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

SELL
$33.72 - $48.22 $4,215 - $6,027
-125 Closed
0 $0
Q3 2021

Nov 05, 2021

SELL
$49.26 - $74.5 $3,694 - $5,587
-75 Reduced 37.5%
125 $7,000
Q2 2021

Aug 06, 2021

SELL
$56.91 - $127.53 $7,113 - $15,941
-125 Reduced 38.46%
200 $15,000
Q1 2021

Apr 29, 2021

BUY
$79.79 - $126.29 $25,931 - $41,044
325 New
325 $30,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $716M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.